FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to modified human erythropoietin (hEPO), and can be used in medicine for treating such pathologies as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), motor neuron diseases, Huntington's disease and spinocerebellar atrophies. Proposed modified hEPO is characterized by content of mutation in binding site with homodimeric or heterodimeric receptor by adding consensus glycosylation sites. Mutation is selected from the following: (a) Lys45Asn and Asn47Thr, (b) Ser104Asn or (c) Gly151Asn and Leu153Thr and the modified hEPO contains an amino acid sequence selected from SEQ ID NO: 4, SEQ ID NO: 18 or SEQ ID NO: 24.
EFFECT: invention provides obtaining modified hEPO with erythropoietic activity less than 0.5% relative to native erythropoietin, which retains neuroprotective and neuroplastic capacity.
5 cl, 18 dwg, 4 tbl
| Title |
Year |
Author |
Number |
| TREATMENT OF ABNORMAL VISCERAL FAT DEPOSITION WITH FIBROBLAST GROWTH FACTOR 3 (sFGFR3) SOLUBLE POLYPEPTIDES |
2018 |
- Guz, Elvire
- Garsiya, Stefani
|
RU2794170C2 |
| POLYPEPTIDES THAT ARE SOLUBLE RECEPTORS OF FIBROBLAST GROWTH FACTOR 3 (sFGFR3), AND WAYS OF THEIR APPLICATION |
2017 |
- Guz, Elvire
- Garsiya, Stefani
|
RU2751483C2 |
| GENE THERAPY OF HYPOPHOSPHATEMIC DISEASES ASSOCIATED WITH FIBROBLAST GROWTH FACTOR 23 |
2020 |
- Rontsitti, Dzhuzeppe
- Zhoz, Luiza
- Sharl, Severin
- Mingotstsi, Frederiko
|
RU2815545C2 |
| USE OF THE ANTI-O-ACETYLATED GANGLIOSIDE GD2 ANTIBODY FOR IMPROVING THE THERAPEUTIC POTENTIAL OF DRUGS |
2017 |
- Birkl, Stefan
- Flerans, Zhyulen
- Farazh, Sebastyan
- Le Dussal, Zhan-Mark
- Koshonno, Deni
- Term, Mikael
- Assulin, Brizhitt
|
RU2771173C2 |
| ISOLATED HUMAN CD45RC ANTIBODY, NUCLEIC ACID, EXPRESSION VECTOR, CELL, PHARMACEUTICAL COMPOSITION, USE THEREOF, IN VITRO METHOD OF DETECTING hCD45RC |
2019 |
- Guilionneau, Carole
- Anegon, Ignacio
|
RU2826421C2 |
| VARIANTS OF ACID ALPHA-GLUCOSIDASE AND THEIR USE |
2017 |
- Mingozzi, Federico
- Ronzitti, Giuseppe
|
RU2780410C2 |
| NOVEL FUSION PROTEINS SPECIFIC FOR CD137 AND GPC3 |
2020 |
- Bel Aiba, Rachida Siham
- Bossenmaier, Birgit
- Jaquin, Thomas
- Peper-Gabriel, Janet
- Hansbauer, Eva-Maria
- Schlosser, Corinna
- Olwill, Shane
|
RU2814653C2 |
| FUSED POLYPEPTIDE WITH ANTI-CANCER ACTIVITY |
2016 |
- Schlosser, Corinna
- Olwill, Shane
- Rothe, Christine
- Bel Aiba, Rachida Siham
- Hinner, Marlon
|
RU2754466C2 |
| STABLE COMPOSITIONS OF ANTI-TIGIT ANTIBODIES, INDIVIDUALLY AND IN COMBINATION WITH ANTIBODIES AGAINST PROGRAMMED DEATH RECEPTOR 1 (PD-1), AND METHODS OF THEIR USE |
2018 |
- De, Arnab
- Narasimkhan, Chakravarti Nachu
|
RU2820576C2 |
| NOVEL FUSION PROTEIN SPECIFIC FOR CD137 AND PD-L1 |
2019 |
- Pavlidu, Marina
- Pattarini, Lyuchiya
- Sholer-Dairel, Aliks
- Rote, Kristina
- Olvill, Shejn
- Bel Ajba, Rashida
- Khinner, Marlon
- Peper, Zhanet
|
RU2818349C2 |
